Jaundice resident survival guide: Difference between revisions
No edit summary |
|||
Line 122: | Line 122: | ||
==Treatment== | ==Treatment== | ||
Based on the liver function tests and CBC,patients with Jaundice will typically fall into one of 3 categories.<ref name="pmid15684121">{{cite journal |vauthors=Giannini EG, Testa R, Savarino V |title=Liver enzyme alteration: a guide for clinicians |journal=CMAJ |volume=172 |issue=3 |pages=367–79 |date=February 2005 |pmid=15684121 |pmc=545762 |doi=10.1503/cmaj.1040752 |url=}}</ref> | |||
{{familytree/start |summary=PE diagnosis Algorithm.}} | {{familytree/start |summary=PE diagnosis Algorithm.}} | ||
{{familytree | | | | | | | |A01| | |A01= ''' Jaundice''' }} | {{familytree | | | | | | | |A01| | |A01= ''' Jaundice''' }} | ||
Line 139: | Line 139: | ||
{{familytree | | | | | | G01 | | G02 | | | | | | G03 | | G04 | |G01=Preoperative biliary decompression (ERCP or PTC)<br>Cholecystectomy<br>endoscopic stenting,surgery<br>excision of cyst |I02=If resecteable, consult surgery<br> If unresectable<br> Pallative therapy,biliary decompression ||G02=If resectable,fit for surgery<br>If unresecatable,pallative therapy |G03=Compensated Cirrhosis Mangament<br>Alochol abstinence<br> Antiviral medications for viral hepatitis<br> avoidance of hepatotoxic medications<br>vaccination|G04=Decompensated Cirrhosis Managment(with complications)<br>Managment of complications:<br>Varices,Asciets,Hepatorenal syndrome,Hepatic encephalopathy }} | {{familytree | | | | | | G01 | | G02 | | | | | | G03 | | G04 | |G01=Preoperative biliary decompression (ERCP or PTC)<br>Cholecystectomy<br>endoscopic stenting,surgery<br>excision of cyst |I02=If resecteable, consult surgery<br> If unresectable<br> Pallative therapy,biliary decompression ||G02=If resectable,fit for surgery<br>If unresecatable,pallative therapy |G03=Compensated Cirrhosis Mangament<br>Alochol abstinence<br> Antiviral medications for viral hepatitis<br> avoidance of hepatotoxic medications<br>vaccination|G04=Decompensated Cirrhosis Managment(with complications)<br>Managment of complications:<br>Varices,Asciets,Hepatorenal syndrome,Hepatic encephalopathy }} | ||
{{familytree/end}} | {{familytree/end}} | ||
==Do's== | ==Do's== |
Revision as of 23:11, 15 August 2020
Jaundice Resident Survival Guide |
---|
Overview |
Causes |
Diagnosis |
Treatment |
Do's |
Don'ts |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Synonyms and keywords:
Overview
The classic definition of Jaundice is a serum bilirubin level higher than 2.5 to 3 mg per dL (42.8 to 51.3 μper L) in conjunction with a clinical picture of yellow skin and sclera. Bilirubin metabolism takes place in three phases; "prehepatic", "intrahepatic", and "posthepatic". The causes of jaundice can be classified under these categories by measuring total bilirubin and its conjugated and unconjugated levels determine where is the dysfunction of bilirubin metabolism.
Causes
Life Threatening Causes
Life-threatening causes include conditions that may result in death or permanent disability within 24 hours if left untreated.
- Ascending cholangitis
- Life threatening cause 2
- Life threatening cause 3
Common Causes
of acute Jaundice[2]
- Gilbert syndrome
- Alcoholic hepatitis
- Viral hepatitis
- Obstructive Jaundice due to Choledocholithiasis or Malignancy
- Decompensated chronic liver disease
of chronic progressive Jaundice
Diagnosis
Shown below is an algorithm summarizing the diagnosis of [[disease name]] according the the [...] guidelines.
Characterize the jaundice duration and frequency ❑ Duration: short versus long ❑ Frequency: episodic vesus constant | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ask about assoaciated symptoms ❑ Abdominal pain (episodic or constant) ❑ Abdominal distension ❑ Fever ❑ Clay colored stool ❑ Dark urine ❑ Weight gain or loss ❑ Anorexia ❑ Dyspepsia ❑ Arthralgia ❑ Myalgia ❑ Back pain ❑ Rash ❑ Confusion | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inquire about ❑ Past medical history ❑ Blood disorder
❑ Family history of ❑ Medication history ❑ Recent travel history
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Examine the patient General Appearance ❑ Check for:
Skin exam
Cariac exam
❑ Check gall bladder area if it is tender
❑ Splenomegaly can be seen in hemolytic states, hodgkin’s, portal hypertension | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Isolated conjugated billirubin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
H01 | H03 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment
Based on the liver function tests and CBC,patients with Jaundice will typically fall into one of 3 categories.[1]
Jaundice | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Managment of isolated unconjugated hyperbilirubinemia If no eveidence of hemolytic anemia consider Gilbert syndrome OR Crigler-Najjar type I, II Work-up and detect the cause of hemolysis, if low Hb,High LDH,Low haptoglobulin, and reticulocytes present G6PD deficiency - mostly recover on its own,if progresses to hemolytic anaemia, oxygen therapy or blood transfusion may be required.Avoid of precipitants and etiological factors Spherocytosis ,phototherapy and/or exchange transfusion for infants, Folic acid for maaintaing erythropoiesis.Splenectomy is the definitive treatment Sickle cell anemia reduce pain and prevent complications, blood transfusions and supplemental oxygen, as well as a bone marrow transplant. Immune related hemolysis – corticosteroids, folic acid is main line of treatment Parasitic Infections like malaria are treated with antimalarial drugs like chloroquine, artesunate, lumefantrine,amodiaquine Ineffective erythropoiesis- iron and folic acid & B12 supplementation, repeated blood transfusions | Managment of isolated conjugated hyperbilirubinemia | Unconjugated & Conjugated hyperbilirubinemia managment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hepatocellular pattern,⇈AST/ALT out of proportion to ALK-P Treatment depends on causes Hepatitis A :mostly self limiting Hepatitis B treated with antiviral medications Hepatitis C is treated with interferons Other Viral infections like EBV, CMV, HSV are treated with Antiviral medications Alcohl hepatitis: Alcohol abstinence,glucocorticoids, pentoxifylline Wilson"s disease:chelating agents such as D-penicillamine Managmenof Acute liver failure Drug toxicity treatment(e.g. Acteaminophen, Isoniazid Primary biliary cholangitis management Auroimmune hepatitis enviromental toxin:kavakava | Cholestatic pattern managment,⇈ Alk-P out of proportion to AST/ALT,predominantly conjugated | Managment of cirrhosis,Predominantly conjugated,↑ INR,↓ Alb,↓ PLt | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dilated Bile ducts | Non-dilated Bile ducts | MELD Score | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Consider Intrahepatic injury | >15 | <15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CBD stones Stricture/choldochal cyst | Solid mass(Extrahepatic) | Consider reffering patient to a transplant center | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preoperative biliary decompression (ERCP or PTC) Cholecystectomy endoscopic stenting,surgery excision of cyst | If resectable,fit for surgery If unresecatable,pallative therapy | Compensated Cirrhosis Mangament Alochol abstinence Antiviral medications for viral hepatitis avoidance of hepatotoxic medications vaccination | Decompensated Cirrhosis Managment(with complications) Managment of complications: Varices,Asciets,Hepatorenal syndrome,Hepatic encephalopathy | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Do's
- The content in this section is in bullet points.
Don'ts
- The content in this section is in bullet points.
References
- ↑ Giannini EG, Testa R, Savarino V (February 2005). "Liver enzyme alteration: a guide for clinicians". CMAJ. 172 (3): 367–79. doi:10.1503/cmaj.1040752. PMC 545762. PMID 15684121.